What landed in the knowledge base, 30 April to 11 May

Coverage moved fast enough over this fortnight that the commit log stopped being a reasonable way to follow it. This is the same work grouped by theme. Everything below is a statement about what was added to the knowledge base, with its trial grounding named — not a treatment recommendation.

Regimen waves

• Haematology — CLL, DLBCL, myeloma and follicular lymphoma: AMPLIFY, POLARIX, TRANSFORM/liso-cel, PERSEUS (D-VRd with ASCT and dara-len maintenance), IKEMA, MURANO/VenR, GADOLIN, AUGMENT.
• Thoracic — NSCLC EGFR (FLAURA-2, MARIPOSA), limited-stage SCLC (ADRIATIC), tarlatamab (DeLLphi-301), perioperative pembrolizumab (KEYNOTE-671), adjuvant atezolizumab (IMpower010), CheckMate-9LA, and second-line nivolumab in mesothelioma (CONFIRM).
• Breast — triple-negative neoadjuvant (KEYNOTE-522) and adjuvant CDK4/6 inhibition in early HR+/HER2−: abemaciclib (monarchE), ribociclib (NATALEE).

Safety and actionability

• Rare-tumour red flags — GIST PDGFRA D842V, medullary thyroid RET, Waldenström CXCR4-WHIM, advanced systemic mastocytosis KIT D816V, dMMR gates, ATLL/AITL/NLPBL, essential thrombocythaemia hydroxyurea resistance, Burkitt ifosfamide.
• CIViC actionability backfill — FLT3 TKD, FOXL2 and KRAS G12V moved onto the evidence_sources block.

Engine and routing

• An ECOG performance status ≥ 4 hard gate.
• English translations of the Ukrainian questionnaires.
• Alignment with МОЗ наказ №473/2026.
• A cross-line-of-therapy routing cleanup across 27 algorithms, correcting output_indications membership so selected indications stop being dropped from rendered plans.

Internal plumbing — validator baselines, upsert batches, session notes — is deliberately left out. It is in the repository for anyone who wants it.